Association of paraoxonase activity and coronary blood flow

Atherosclerosis

Volumn 197, Issue 1, 2008, Pages 257-263

  Yildiz, Ali ^a   Gur, Mustafa ^a   Yilmaz, Remzi ^a   Demirbag, Recep ^a   Polat, Mustafa ^a   Selek, Sahbettin ^a   Celik, Hakim ^a   Erel, Ozcan ^a  

^a HARRAN UNIVERSITY   (Turkey)

Author keywords

Atherosclerosis; Coronary blood flow; Endothelial dysfunction; Paraoxonase; Slow coronary flow

Indexed keywords

ARYLDIALKYLPHOSPHATASE; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; HEMOGLOBIN; PARAOXON; URIC ACID;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; EPICARDIUM; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; HYDROLYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; URIC ACID BLOOD LEVEL;

ADULT; AGED; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; LIPID PEROXIDATION; MALE; MIDDLE AGED; OXIDATIVE STRESS; PARAOXON;

EID: 39449140067     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.04.004     Document Type: Article

References (39)

1. Carew T.E. Role of biologically modified low-density lipoprotein in atherosclerosis. Am J Cardiol 64 (1989) 18G-22G
2. Barter P.J., and Rye K.A. High density lipoproteins and coronary heart disease. Atherosclerosis 121 (1996) 1-12
3. Watson A.D., Berliner J.A., Hama S.Y., et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96 (1995) 2882-2891
4. Aviram M., Rosenblat M., Bisgaier C.L., et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 101 (1998) 1581-1590
5. Pasqualini L., Cortese C., Marchesi S., et al. Paraoxonase-1 activity modulates endothelial function in patients with peripheral arterial disease. Atherosclerosis 183 (2005) 349-354
6. Malin R., Knuuti J., Janatuinen T., et al. Paraoxonase gene polymorphisms and coronary reactivity in young healthy men. J Mol Med 79 (2001) 449-458
7. Granér M., James R.W., Kahri J., et al. Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. J Am Coll Cardiol 47 (2006) 2429-2435
8. Gur M., Aslan M., Yildiz A., et al. Paraoxonase and arylesterase activities in coronary artery disease. Eur J Clin Invest 36 (2006) 779-787
9. Cin V.G., Pekdemir H., Camsar A., et al. Diffuse intimal thickening of coronary arteries in slow coronary flow. Jpn Heart J 44 (2003) 907-919
10. Mosseri M., Yarom R., Gotsman M.S., and Hasin Y. Histologic evidence for small-vessel coronary artery disease in patients with angina pectoris and patent large coronary arteries. Circulation 74 (1986) 964-972
11. Tanriverdi H., Evrengul H., Kuru O., et al. Cigarette smoking induced oxidative stress may impair endothelial function and coronary blood flow in angiographically normal coronary arteries. Circ J 70 (2006) 593-599
12. Sezgin A.T., Sigirci A., Barutcu I., et al. Vascular endothelial function in patients with slow coronary flow. Coron Artery Dis 14 (2003) 155-161
13. Gibson C.M., Cannon C.P., Daley W.L., et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 93 (1996) 879-888
14. Teichholz L.E., Kreulen T., Herman M.V., and Gorlin R. Problems in echo-cardiographic volume determinations: echo-cardiographic-angiographic correlations in the presence or absence of asynergy. Am J Cardiol 37 (1976) 7-11
15. Eckerson H.W., Wyte C.M., and La Du B.N. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 35 (1983) 1126-1138
16. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 37 (2004) 112-119
17. Arab K., and Steghens J.P. Plasma lipid hydroperoxides measurement by an automated xylenol orange method. Anal Biochem 325 (2004) 158-163
18. Pohl U., and Busse R. Endothelium-dependent modulation of vascular tone and platelet function. Eur Heart J 11 Suppl. B (1990) 35-42
19. Shih D.M., Gu L., Xia Y.R., et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394 (1998) 284-287
20. Tward A., Xia Y.R., Wang X.P., et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 106 (2002) 484-490
21. Srinivasan S.R., Li S., Chen W., et al. Q192R polymorphism of the paraoxanase 1 gene and its association with serum lipoprotein variables and carotid artery intima-media thickness in young adults from a biracial community. The Bogalusa Heart Study. Atherosclerosis 177 (2004) 167-174
22. Leus F.R., Wittekoek M.E., Prins J., Kastelein J.J., and Voorbij H.A. Paraoxonase gene polymorphisms are associated with carotid arterial wall thickness in subjects with familial hypercholesterolemia. Atherosclerosis 149 (2000) 371-377
23. Malin R., Jarvinen O., Sisto T., Koivula T., and Lehtimaki T. Paraoxonase producing PON1 gene M/L55 polymorphism is related to autopsy-verified artery-wall atherosclerosis. Atherosclerosis 157 (2001) 301-307
24. Rontu R., Karhunen P.J., Ilveskoski E., et al. Smoking-dependent association between paraoxonase 1 M/L55 genotype and coronary atherosclerosis in males: an autopsy study. Atherosclerosis 171 (2003) 31-37
25. Mackness B., Davies G.K., Turkie W., et al. Paraoxonase status in coronary heart disease. Are activity and concentration more important than genotype?. Arterioscler Thromb Vasc Biol 21 (2001) 1451-1457
26. Leviev I., and James R.W. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 20 (2000) 516-521
27. Wheeler J.G., Keavney B.D., Watkins H., Collins R., and Danesh J. Four paraoxonase gene polymorphisms in 11,212 cases of coronary heart disease and 12,786 controls meta-analysis of 43 studies. Lancet 363 (2004) 689-695
28. Parent R., Pare R., and Lavallee M. Contribution of nitric oxide to dilation of resistance coronary vessels in conscious dogs. Am J Physiol 262 1 Pt 2 (1992) H10-H16
29. Lee C.M., Chien C.T., Chang P.Y., et al. High-density lipoprotein antagonizes oxidized low-density lipoprotein by suppressing oxygen free-radical formation and preserving nitric oxide bioactivity. Atherosclerosis 183 (2005) 251-258
30. Sezgin N., Barutcu I., Sezgin A.T., et al. Plasma nitric oxide level and its role in slow coronary flow phenomenon. Int Heart J 46 (2005) 373-382
31. Bauters C., Amant C., Boulier A., et al. Paraoxonase polymorphism (Gln192Arg) as a determinant of the response of human coronary arteries to serotonin. Circulation 101 (2000) 740-743
32. Ito T., Yasue H., Yoshimura M., Nakamura S., et al. Paraoxonase gene Gln192Arg (Q192R) polymorphism is associated with coronary artery spasm. Hum Genet 110 (2002) 89-94
33. Mashiba J., Koike G., Kamiunten H., Ikeda M., and Sunagawa K. Vasospastic angina and microvascular angina are differentially influenced by PON1 A632G polymorphism in the Japanese. Circ J 69 (2005) 1466-1471
34. Paolisso G., Manzella D., Tagliamonte M.R., et al. The BB-paraoxonase genotype is associated with impaired brachial reactivity after acute hypertriglyceridemia in healthy subjects. J Clin Endocrinol Metab 86 (2001) 1078-1082
35. Epstein S.E., Cannon O., and Talbot T.L. Hemodynamic principles in the control of coronary blood flow. Am J Cardiol 56 (1985) 4E-10E
36. Erdogan D., Caliskan M., Gullu H., et al. Coronary flow reserve is impaired in patients with slow coronary flow. Atherosclerosis 191 (2007) 168-174
37. Roberts W.C., and Jones A.A. Quantitation of coronary arterial narrowing at necropsy in sudden coronary death: analysis of 31 patients and comparison with 25 control subjects. Am J Cardiol 44 (1979) 39-45
38. Ge J., Erbel R., Gerber T., et al. Intravascular ultrasound imaging of angiographically normal coronary arteries: a prospective study in vivo. Br Heart J 71 (1994) 572-578
39. Abaci A., Oguzhan A., Eryol N.K., and Ergin A. Effect of potential confounding factors on the thrombolysis in myocardial infarction trial frame count and its reproducibility. Circulation 100 (1999) 2219-2223